Cybin (CYBN) announced completion of enrollment in its Phase 2 study evaluating CYB004, a proprietary deuterated dimethyltryptamine program, for the treatment of generalized anxiety disorder and reaffirms top line data guidance expected in the first quarter of 2026.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CYBN:
- Psychedelic: Bright Minds reports preclinical BMB-201 results
- Cybin to Engage at H.C. Wainwright Investment Conference
- Cybin to Engage at Cantor Global Healthcare Conference 2025
- Morning Movers: United Therapeutics surges after TETON-2 met primary endpoint
- Cybin Announces Leadership Transition with Eric So as Interim CEO